Core Insights - CDT Equity Inc. has announced a collaboration with Sarborg Limited to utilize an expanded rare disease signature database for mapping its asset portfolio [3][5] - Sarborg has curated a database of approximately 1,700 rare disease signatures, enhancing its existing library of over 1,600 conditions, which will facilitate rapid analysis of disease relationships and therapeutic opportunities [2][3] Company Overview - CDT Equity Inc. is a data-driven biopharmaceutical development company focused on advancing high-potential therapeutic assets through scientific innovation and strategic partnerships [5] - The company aims to create shareholder value through licensing, strategic mergers and acquisitions, and positioning itself as a platform for transformative innovation [5] Collaboration Details - The collaboration with Sarborg will allow CDT to maximize its intellectual property position and explore commercialization opportunities through external partnerships [3] - CDT holds a 20% equity stake in Sarborg and continues to leverage its cross-industry signature intelligence platform [3]